Home Clinical usefulness of measuring red blood cell distribution width on admission in patients with acute coronary syndromes
Article
Licensed
Unlicensed Requires Authentication

Clinical usefulness of measuring red blood cell distribution width on admission in patients with acute coronary syndromes

  • Giuseppe Lippi , Luca Filippozzi , Martina Montagnana , Gian Luca Salvagno , Massimo Franchini , Gian Cesare Guidi and Giovanni Targher
Published/Copyright: February 4, 2009

Abstract

Background: Conventional cardiac markers used for the biochemical diagnosis of acute coronary syndromes (ACS) have a high specificity but low sensitivity within 2–4 h of symptoms onset. The red blood cell distribution width (RDW), reflecting the size variability of circulating red blood cells, has been shown to be independently associated with an increased risk of major cardiovascular events. We assessed whether there is an association between RDW at admission and cardiac troponin T (cTnT) elevation in patients with chest pain.

Methods: We analyzed RDW values in 2304 adult patients, who were consecutively admitted over a 1-year period to the local emergency department for chest pain suggestive of ACS. In all patients, a baseline blood sample was collected for routine haematological testing, whereas cTnT was measured at baseline and after 4, 6, and 12 h.

Results: A total of 456 patients (19.8% of total) had ACS. These patients, all having cTnT≥0.03 μg/L up to 12 h from admission other than ischaemic electrocardiographic changes, had higher RDW than non-ACS patients [median 15.1%, (5th–95th percentiles) 13.2%–19.0% vs. 13.5%, 12.9%–17.1%, p<0.001]. On admission, the sensitivity and specificity of cTnT were 94% (25 false negative results) and 100%, respectively. The diagnostic accuracy of RDW, as calculated by the receiver operating characteristic curve analysis, was 0.705 (p<0.001). At the cut-off value of 14%, the clinical sensitivity and specificity of RDW on admission were 79% and 50%, respectively. In 21 out of 25 patients classified as false negative for cTnT on admission, the RDW was >14%. Accordingly, the diagnostic sensitivity of the two combined measurements on admission was 99%.

Conclusions: As RDW is widely available to clinicians as a part of the complete blood count, and therefore incurs no additional costs, it might be considered with other conventional cardiac markers for the risk stratification of ACS patients admitted to emergency departments.

Clin Chem Lab Med 2009;47:353–7.


Corresponding author: Prof. Giuseppe Lippi, MD, Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università degli Studi di Verona, Ospedale Policlinico G.B. Rossi, Piazzale Scuro, 10, 37134 – Verona, Italy Phone: +39-045-8126698, Fax: +39-045-8201889,

Received: 2008-5-19
Accepted: 2008-11-25
Published Online: 2009-02-4
Published in Print: 2009-03-01

©2009 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Dipeptidyl peptidases and related proteins: Editorial
  2. Dipeptidyl peptidases and related proteins: multifaceted markers and therapeutic targets
  3. Dipeptidyl peptidases and related proteins: Reviews
  4. Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside
  5. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions
  6. Dipeptidyl peptidase (DP) 6 and DP10: novel brain proteins implicated in human health and disease
  7. Dipeptidyl peptidases and related proteins: Original Papers
  8. Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice
  9. Original Papers
  10. Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions
  11. Genetics and Molecular Diagnostics
  12. A selected pre-amplification strategy for genetic analysis using limited DNA targets
  13. Automated cell disruption is a reliable and effective method of isolating RNA from fresh snap-frozen normal and malignant oral mucosa samples
  14. General Clinical Chemistry and Laboratory Medicine
  15. Serum free light chain immunoassay as an adjunct to serum protein electrophoresis and immunofixation electrophoresis in the detection of multiple myeloma and other B-cell malignancies
  16. Gas chromatography/mass spectrometry screening of serum metabolomic biomarkers in hepatitis B virus infected cirrhosis patients
  17. Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers
  18. Sensitive and specific ELISA coated by TpN15-TpN17-TpN47 fusion protein for detection of antibodies to Treponema pallidum
  19. Cardiovascular Diseases
  20. Expression of heme oxygenase-1, hypoxia inducible factor-1α, and ubiquitin in peripheral inflammatory cells from patients with coronary heart disease
  21. Vitamin B12 deficiency is associated with coronary artery disease in an Indian population
  22. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease
  23. Association of polymorphisms of PTGS2 and CYP8A1 with myocardial infarction
  24. Clinical usefulness of measuring red blood cell distribution width on admission in patients with acute coronary syndromes
  25. Validation and Outcome Studies
  26. Evaluation of the BD Vacutainer® PST™ II Blood Collection Tube for special chemistry analytes
  27. Higher parathyroid hormone (PTH) concentrations with the Architect PTH assay than with the Elecsys assay in hemodialysis patients, and a simple way to standardize these two methods
  28. Precision performance at low levels and 99th percentile concentration of the Access® AccuTnI® assay on two different platforms
  29. Guidelines and Recommendations
  30. The European Register of Specialists in Clinical Chemistry and Laboratory Medicine: Code of Conduct, Version 2 – 2008
  31. Letters to the Editor
  32. A preliminary evaluation of the AQT90 FLEX TnI immunoassay
  33. Automated validation of clinical laboratory test results: do we get what we expect?
  34. The degree of knowledge shown by physicians in relation to the variability of laboratory test results
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2009.066/html
Scroll to top button